Healthy
Conditions
Brief summary
The purpose of this study is to assess the safety and tolerability of daratumumab following a single subcutaneous (SC) administration in healthy participants and to determine whether premedication with corticosteroids is required to improve the tolerability of SC administration of daratumumab in healthy participants.
Interventions
DRUGDaratumumab
Single SC dose of daratumumab will be administered in each of 8 dose cohorts.
DRUGPlacebo
Placebo liquid will be administered as SC dose in each of first 7 dose cohorts.
DRUGrHuPH20
Participants in Cohort 8 will receive single SC dose of rHuPH20 as a part of daratumumab formulation.
Sponsors
Janssen Research & Development, LLC
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Must have a body weight in the range of 50 to 100 kilogram (kg), inclusive, and have a body mass index (BMI) of 19 to 30 kilogram per meter square (kg/m\^2), inclusive, at screening and Day -1 * Must be otherwise healthy on the basis of physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at screening and Day -1 * Must be otherwise healthy on the basis of clinical laboratory tests performed at screening and Day -1 * A woman must not be of childbearing potential * Must be a non-smoker or tobacco user or 3 months prior to screening
Exclusion criteria
* Pregnant or breastfeeding while enrolled in this study or within 20 weeks after the dose of study treatment * History of or currently has any clinically significant medical illness or medical disorders the investigator considers significant, including, but not limited to immune deficiency state, liver or renal insufficiency, significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances * Has a history of malignancy before screening. Exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or a malignancy which is considered cured with minimal risk of recurrence * Active acute or chronic infection (including chronic recurrent or invasive candidiasis) or diagnosed latent infection * Has had a Bacille Calmette-Guérin (BCG) vaccination within 12 months of screening and/or plan to receive a BCG vaccine within 12 months after the administration of study treatment * Has experienced a recent single dermatomal herpes zoster eruption within the past 6 months * Has a history of multi-dermatomal herpes zoster or central nervous system (CNS) zoster within the past 5 years * Has received prescription medications within 14 days prior to study treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of Participants With Treatment-Emergent Adverse Event (TEAEs) by Severity Through Day 141 Versus Placebo | Up to Day 141 | The safety and tolerability of daratumumab following a single subcutaneous (SC) administration in healthy participants will be assessed. |
| Proportion of Participants With TEAEs by Serious Adverse Events (SAEs) Through Day 141 Versus Placebo | Up to Day 141 | The safety and tolerability of daratumumab following a single subcutaneous (SC) administration in healthy participants will be assessed. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to the Time Corresponding to the Last Quantifiable Serum Concentration (AUC [0-last]) | Day 1 predose through Day 141 | AUC (0-last) is the area under the plasma concentration-time curve from time zero to the time corresponding to the last quantifiable serum concentration. |
| Area Under the Plasma Concentration-time Curve From Time Zero to Infinity With Extrapolation of the Terminal Phase (AUC[0- infinity]) | Day 1 predose through Day 141 | AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinity with extrapolation of the terminal phase, calculated as the sum of AUC(last) and C(last)/lambda(z); wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant. |
| Maximum Observed Plasma Concentration (Cmax) | Day 1 predose through Day 141 | Cmax is the maximum observed plasma concentration. |
| Number of Participants With Anti-recombinant Human Hyaluronidase (rHuPH20) Antibodies | Day 1 predose through Day 141 | Number of participants who test positive for anti-rHuPH20 antibodies will be reported. |
| Percentage of CD38 Expression Levels and CD38 Expressing Cell Counts Measured by Flow Cytometry | Day 1 predose through Day 141 | The cluster of differentiation (CD) 38 expression levels and CD38 expressing cell counts, as measured by flow cytometry, will be summarized. |
| Number of Participants With Anti-daratumumab Antibodies | Day 1 predose through Day 141 | Number of participants who test positive for anti-daratumumab antibodies will be reported. |
| Time to the Maximum Observed Plasma Concentration (Tmax) | Day 1 predose through Day 141 | Tmax is defined as actual sampling time to reach maximum observed plasma concentration. |
Countries
United States
Outcome results
None listed